Pramlintide vs Semaglutide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes, and investigated for weight management due to amylin's central role in meal-related satiety signaling. Amylin is co-secreted with insulin from pancreatic beta-cells and slows gastric emptying, suppresses post-meal glucagon release, and activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem. Randomized controlled trials demonstrate that subcutaneous pramlintide administration before meals significantly reduces 24-hour caloric intake, meal sizes, and body weight in obese subjects, with effects independent of glycemic control. Pramlintide is an FDA-approved prescription medication (Symlin); its weight management application is off-label in non-diabetic patients, and use requires monitoring for hypoglycemia, particularly when co-administered with insulin. Pramlintide vs cagrilintide: the amylin analogue generation gap Pramlintide (Symlin) is a first-generation amylin analogue with a short half-life requiring injection before each meal — typically 60–120mcg per meal in T1D, or 120mcg per meal in T2D — making three daily injections standard. Cagrilintide, currently in Phase 3 development, is a long-acting amylin analogue designed for once-weekly subcutaneous administration, combining with semaglutide in the CagriSema combination. The practical distinction is significant: pramlintide's thrice-daily injection burden limits adherence, particularly in non-diabetic weight management contexts. Cagrilintide's weekly dosing removes this barrier and enables combination with a weekly GLP-1 agonist in a single injection protocol. Pramlintide for weight management: In adults without diabetes, pramlintide produces modest mean weight reductions of 3–5% over 6-month studies — less than GLP-1 agonists but with a complementary mechanism. Some researchers have combined pramlintide with a GLP-1 agonist (pramlintide + GLP-1) as an early-generation dual amylin/incretin approach, reporting additive weight reductions. CagriSema (cagrilintide + semaglutide) in Phase 3 represents the pharmacologically optimised version of this dual approach, with superior efficacy and weekly dosing. Pramlintide's practical role in new weight management programs has therefore narrowed significantly as cagrilintide and GLP-1/amylin combinations approach approval.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Mechanism of action: Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors in the hypothalamus, brainstem, and pancreas. This triggers a coordinated metabolic response: appetite signals are reduced, gastric emptying is slowed (increasing satiety duration), insulin secretion is potentiated in a glucose-dependent manner, and glucagon secretion is suppressed. The result is reduced caloric intake and improved postprandial glucose regulation. Semaglutide's extended half-life (~7 days) enables once-weekly subcutaneous injection, distinguishing it from earlier GLP-1 agonists that required daily dosing. Clinical evidence: The STEP trial program established semaglutide's weight reduction profile. STEP 1 (2021) found a mean weight reduction of 14.9% over 68 weeks with 2.4mg/week semaglutide (Wegovy dose) vs 2.4% with placebo. STEP 4 demonstrated that discontinuation led to weight regain, indicating ongoing use is required to maintain outcomes. The SUSTAIN trial series confirmed cardiovascular risk reduction in T2D patients. Semaglutide is one of the most extensively studied GLP-1 agonists in large-scale randomised controlled trials. Semaglutide with B12: Some compounding formulations combine semaglutide with vitamin B12 (methylcobalamin) in the same injectable preparation. The rationale is two-fold: nausea and gastrointestinal discomfort are the most commonly reported side effects of GLP-1 agonists (occurring in 15–40% of users in trials), and injectable methylcobalamin bypasses the reduced gastric absorption that can accompany slowed gastric motility. B12 also supports energy metabolism during periods of caloric restriction. Clinical evidence that B12 addition changes weight loss outcomes is limited; the combination is primarily a compounding convention rather than a protocol validated in independent clinical trials. Providers offering compounded semaglutide with B12 formulations are indexed in the PeptideBase directory. Semaglutide vs tirzepatide: Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The SURMOUNT-5 head-to-head trial found tirzepatide produced greater weight reductions than semaglutide at comparable doses. Both are FDA-approved and available through licensed prescribers; protocol selection depends on clinical context and provider judgment.